Publications by authors named "Rachel N Lowe"
Article Synopsis
- The study examines how often clinicians take action to monitor or reduce risks associated with medications that can prolong QTc intervals in outpatient settings.
- It involved reviewing medical records of nearly 400 prescriptions and assessing whether clinicians addressed modifiable risk factors for QTc-prolongation within 48 hours of prescribing these medications.
- Results showed that although a significant portion of patients had potential laboratory-related risk factors, only a small percentage of those risks were acknowledged and acted upon by clinicians.
Centrally supported clinical pharmacist intervention to reduce clinical inertia in hypertension.
Am J Health Syst Pharm
March 2023
Purpose: To assess the impact of a one-time hypertension (HTN)-focused clinical pharmacist intervention on the occurrence of clinical inertia and change in blood pressure (BP).
Methods: This retrospective study included patients 18 to 89 years of age with a current diagnosis of HTN and average systolic BP of ≥150 mm Hg. Centralized outreach coordinators performed telephone outreach to patients to schedule an HTN-focused visit with their primary care provider (PCP) and forwarded outreach notes for half of these patients to clinical pharmacists embedded in an internal medicine clinic.
Hypoglycaemia is a complication associated with the management of both type 1 and type 2 diabetes. Despite newer technologies to help minimize the risk of hypoglycaemia, it remains a barrier for some patients to achieve optimal glycaemic control. In this review, the definitions and risk factors for hypoglycaemia will be briefly discussed and an in-depth review of the management for a conscious or unconscious patient in the outpatient and inpatient settings is provided.
View Article and Find Full Text PDFBackground: The 2018 AHA/ACC/multisociety cholesterol guideline emphasizes the need for lipid monitoring more strongly than the previous 2013 guideline to ensure patients reach recommended percent low-density lipoprotein cholesterol reductions. Real-world compliance to monitoring recommendations is currently unknown.
Objectives: This study examined the proportion of patients with a lipid panel measured within 3 months of statin initiation.
To review the safety, efficacy, and administration of intranasal (IN) glucagon for the management of hypoglycemia. A literature search of PubMed/MEDLINE (1995 to November 2019) using the terms , and was completed. English-language studies evaluating IN glucagon were evaluated.
View Article and Find Full Text PDFObjective: The objective is to review the evidence evaluating the efficacy of statin therapy for primary prevention of cardiovascular (CV) disease in the elderly.
Data Sources: A literature search of MEDLINE and PubMed (1966-January 2013) using the terms HMG-CoA reductase inhibitor, statin, primary prevention, elderly, and geriatrics was performed. The search was limited to clinical trials, meta-analyses, and subanalyses, including primary prevention patients.
Objective: To describe safety and efficacy laboratory monitoring of statin therapy at the University of Colorado Hospital Outpatient Clinics over a period of 3 years prior to the revised United States Food and Drug Administration statin labeling.
Methods: This retrospective, observational study evaluated serum laboratory monitoring for safety and efficacy of statin therapy between July 2008 and June 2011. Adult patients prescribed chronic statin therapy were included.